Foam composite for the repair or regeneration of tissue
The present patent describes a biocompatible composite made of a first fibrous layer attached to a three-dimensional inter-connected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These composites can be made from blends of absorbable and biocompatible polymers. These biocompatible composites are particularly well suited to tissue engineering applications and can be designed to mimic tissue transition or interface zones.
1. A method for the repair or regeneration of tissue comprising contacting cells with a biocompatible composite comprising a first biocompatible filamentous layer attached to a second biocompatible foam layer wherein the biocompatible foam is selected from the group consisting of gradient foams and channeled foams; wherein the biocompatible gradient foam has a first location and a second location wherein the biocompatible gradient foam has a substantially continuous transition in at least one characteristic selected from the group consisting of composition, stiffness, flexibility, bioabsorption rate and pore architecture from the first location to the second location of said biocompatible gradient foam and the channeled foam has a first surface and a second surface with channels therein.
2. The method of claim 1 wherein the biocompatible composite is bioabsorbable.
3. The method of claim 1 wherein the biocompatible composite is made from a bioabsorbable polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups poly(anhydrides), polyphosphazenes, biopolymers and blends thereof.
4. The method of claim 3 wherein the bioabsorable polymer is an aliphatic polyester.
5. The method foam of claim 4 wherein the aliphatic polyester is selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.
6. The method of claim 5 wherein the aliphatic polyester is an elastomer.
7. The method of claim 1 wherein cells are seeded onto the biocompatible composite.
8. The method of claim 5 wherein cells are seeded onto the biocompatible composite.
9. The method of claim 1 wherein the biocompatible composite is implanted in an animal and contacted with cells.
10. The method of claim 5 wherein the biocompatible composite is implanted in an animal and contacted with cells.
11. The method of claim 1 wherein the biocompatible composite is seeded with cells and the biocompatible composite and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible composite.
12. The method of claim 5 wherein the biocompatible composite is seeded with cells and the biocompatible composite and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible composite.
13. The method of claim 1 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.
14. The method of claim 1 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.
15. The method of claim 1 wherein the biocompatible composite contains an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.
16. A method of claim 1 wherein the biocompatible composite is formed from a composition containing in the range of from about 30 weight percent to about 99 weight percent ε-caprolactone repeating units.
17. The method foam of claim 16 wherein the ε-caprolactone repeating units are polymerized with a comonomer selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.
18. The method of claim 16 wherein cells are seeded onto the biocompatible composite.
19. The method of claim 16 wherein the biocompatible foam is implanted in an animal and contacted with cells.
20. The method of claim 16 wherein the biocompatible composite is seeded with cells and the biocompatible composite and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible composite.
21. The method of claim 20 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.
22. The method of claim 20 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.